This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Social Bookmarking   What's this?

Jose A. Yaryura Tobias, MD; Sidney Merlis, MD
Central Islip (NY) State Hospital

JAMA. 1970;211(11):1857.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

To the Editor.—

The use of levodopa (L-DOPA; dihydroxyphenylalanine) for the treatment of Parkinson's disease has been satisfactorily demonstrated in many cases when other therapeutic measures fail to act. It has been reported in the available literature^1,2 that the administration of levodopa might cause psychiatric symptoms (eg, hallucinations, ideas of reference, or irritability) as untoward side effects.

Our own experience indicates that levodopa aggravates the mental status of patients with chronic schizophrenia with drug-induced parkinsonism.³ We have also found that levodopa increased the severity of depression in two patients with Parkinson's disease and caused auditory and visual hallucinations in one patient without previous mental illness. A decrease or gradual withdrawal of levodopa resulted in the disappearance of psychiatric symptoms in all three patients. These findings could be in agreement with those biochemical theories of schizophrenia where biogenic amines metabolism seems to play a preponderant role.⁴ As this . . . [Full Text PDF of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?